Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART) - Takeaways - MDSpire

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

  • April 23, 2026

  • 4 min

Share

  • 1

    The DE-CART trial evaluates adaptive SBRT as a treatment for intermediate- or high-risk prostate cancer.

  • 2

    Participants receive adaptive SBRT every other day for a total of 5 treatment sessions over 2 to 3 weeks.

  • 3

    Inclusion criteria require histologically confirmed prostate adenocarcinoma and specific imaging results.

  • 4

    Exclusion criteria include prior pelvic radiation therapy and uncontrolled intercurrent illnesses.

  • 5

    Follow-up assessments occur at 6 weeks, 90 days, and then regularly for the first year post-treatment.

Original Source(s)

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

  • April 23, 2026

Related Content

Diagnostic accuracy of 1H-MRS in detecting the oncometabolite 2-hydroxyglutarate (2HG) in adult-type diffuse gliomas

Explainable AI in Cancer Imaging: Scoping Review of Methods, Modalities, and Clinical Integration

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals

This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.